Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122185 · ClinicalTrials.gov registry record · Phase 2
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 2 study of Ovarian Endometrioid Adenocarcinoma and Recurrent Ovarian Epithelial Cancer, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 10
- Study locations
NCT02122185 is a Phase 2 study of Ovarian Endometrioid Adenocarcinoma and Recurrent Ovarian Epithelial Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 110 participants, below the 295-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (63% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT02122185, a Phase 2 study of Ovarian Endometrioid Adenocarcinoma and Recurrent Ovarian Epithelial Cancer, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 10
- Study locations
Study Summary
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help carboplatin, paclitaxel and docetaxel work better by making tumor cells more sensitive to the drugs. Studying samples of blood and tissue in the laboratory from patients receiving metformin hydrochloride may help doctors learn more about the effects of metformin hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. Giving metformin hydrochloride together with combination chemotherapy may kill more tumor cells.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Chemotherapy
- DRUG metformin hydrochloride
Study Locations (10)
Illinois
- NCH Medical Group- Northwest Community Hospital - Arlington Heights
- Rush University Medical Center - Chicago
- University of Chicago - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem - Evanston
- Ingalls Memorial Hospital - Harvey
Alabama
- University of Alabama - Birmingham
- Mitchell Cancer Institute - University of South Alabama - Mobile
California
- City of Hope - Duarte
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-02-25 |
| Est. Completion | 2027-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02122185
The ClinicalTrials.gov registry entry for NCT02122185 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 295-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (63% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT02122185 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT02122185 about?
NCT02122185 is a clinical study titled "Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways t...
What is the current status of trial NCT02122185?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2015-02-25. Estimated completion is 2027-02-25.
What conditions does trial NCT02122185 study?
This clinical trial studies the following conditions: Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Cancer, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma.
What interventions are being tested in trial NCT02122185?
The interventions under investigation include: placebo (DRUG), Chemotherapy (DRUG), metformin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02122185?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02122185 being conducted?
This trial has 10 study locations across Alabama, California, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
RECRUITING · Phase 2
-
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
COMPLETED · Phase 2
Explore more on PlainTrial
Ovarian Endometrioid Adenocarcinoma
All registered trials for this condition
Recurrent Ovarian Epithelial Cancer
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.